Last updated: Nov 17, 2026, 12:00 AM

Basler Kantonalbank Exchange (SW, CHF)

BSKP.SW

108.60
0.00 (0.00%)
Financial ServicesBanks - Regional
Invest Today
Invest Today
1 year return (CAGR)
35.66%
3 year return (CAGR)
19.22%
5 year return (CAGR)
11.55%
10 year return (CAGR)
4.84%
Stock Analysis

Adobe 2026 Q3 – Is sentiment driving the price?

Read More
Marketcap
554.85M
Price/Sales
0.20
Ent value
48.49B
Price/Book
0.12
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
100.09%
Trailing P/E
1.37
PEG
-
Forward P/E
-
EPS growth
-25.52%

Stock information

iO Charts Blog

What is a stock exchange? Operation, actors, examples

Read More

Stock chart

Loading...
Stock price data
Open109.40
Daily high110.00
Daily low108.20
Daily Volume1K
All-time high770.00
1y analyst estimate-
Beta0.17
EPS (TTM)9.88
Dividend per share0.00
Ex-div date27 Mar 2026
Next earnings date25 Mar 2026

Ready to capitalize on Basler Kantonalbank's growth potential?

Take the next step in your portfolio.

Invest Today

Downside potential

Loading...
Downside potential data
BSKP.SWS&P500
Current price drop from All-time high-85.90%-5.99%
Highest price drop-92.39%-56.47%
Date of highest drop29 Sep 20229 Mar 2009
Avg drop from high-75.68%-10.64%
Avg time to new high37 days12 days
Max time to new high7125 days1805 days
News
Boost ROI with AI analytics, decentralized monitoring, EDC, stronger patient recruitment and retention, expanded lab capacity, and rigorous compliance.Dublin, Nov. 18, 2026 (GLOBE NEWSWIRE) -- "Allerg...
November 18, 2026
Pelabresib 144-week Phase III MANIFEST-2 data show sustained clinical effects in longest follow-up from a combination trial in first-line JAKi-naïve myelofibrosisKISQALI® six-year NATALEE analysis dee...
November 18, 2026
Gas markets are in flux, LNG cargoes are harder to secure, and Asia is quietly burning more coal again. That mix is unsettling for energy users, but it can reshape earnings power for companies tied to...
November 18, 2026
Boost ROI through next-gen delivery platforms that differentiate biologics, extend patent life, enable precision therapies and meet demand for non-invasive, connected care.Dublin, Nov. 17, 2026 (GLOBE...
November 17, 2026
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round.
November 17, 2026
On Tuesday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) Cosentyx (secukinumab) 150 mg to treat adults with polymyalgia rheumatica (PMR) who respond inadequately to co...
November 17, 2026
Incyte secures EC approval for Povofortay, the first once-daily oral HS treatment in the EU, opening a new growth opportunity backed by strong clinical results.
November 17, 2026
Roche wins FDA approval for Wilserdly plus everolimus, offering an all-oral treatment option for advanced breast cancer and strengthening its oncology portfolio.
November 17, 2026